A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a standard "3+3" Phase 1b study to determine the MTD of Oraxol (paclitaxel + HM30181
Methanesulfonate monohydrate) in subjects with advanced malignancies that may be metastatic
or unresectable with measurable malignant lesion(s) per RECIST Version 1.1 criteria.
Phase:
Phase 1
Details
Lead Sponsor:
Kinex Pharmaceuticals Inc Kinex Pharmaceuticals Inc.